Compare Ovintiv Inc. (DE) (OVV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ovintiv Inc. (DE) vs Tango Therapeutics Inc. — how do they compare? Ovintiv Inc. (DE) trades at $66.75 (market cap $18.44B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Ovintiv Inc. (DE) is far larger — about 4.9× Tango Therapeutics Inc.'s market cap, and Ovintiv Inc. (DE) pays a 1.8% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ovintiv Inc. (DE) for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| OVV | TNGX | |
|---|---|---|
Market Cap | $18.44B | $3.75B |
Volume | 3,495,725 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $66.97 | $32.90 |
52-Week Low | $35.97 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.77B | $2.77B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OVV trades at $66.66, up 2.36% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing robust revenue growth. Recent news highlights expansion in Permian and Montney assets, share buybacks, and strong free cash flow generation, positioning the stock for potential upside.
The outlook for OVV is positive, driven by operational strength and strategic acquisitions, though risks include commodity price volatility and natural gas headwinds. With a consensus price target of $76.00 and no sell ratings, Wall Street sentiment remains bullish, offering a favorable risk-reward profile for investors seeking energy exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
